Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe as an infamous example of a horribly wrong decision in law schools for decades
I'm a 44yr master auto tech. I'm expert at diagnosis of anything that burns gas. IMO this Judge is in way over her head when it comes to clinical trials.she's a lawyer not a Dr. & knows just enough about pharmaceuticals to poison her dog.
Adcom nightmares ,,,shades of? I respectfully beg to differ with those who think there were no dirty goings on with the infamous adcom years past. Its really hard for me to reconcile this judges expertise with this obviously flawed decision. What ever Amrn does I hope they see the need to use the best Lawyers money can buy and absolutely blow the other side out of the water!!!! I hope they realize know that although they should play by the rules ,, an all out effort is required. I'm sure the
Legal efforts to win have been very good, but in this case you need to buck up and get the best money can buy. To me for what ever reason somebody has it in for Amarin. No more assumptions that we are going to win.
I guess no computer chip patents are valid then because they've been in production for decades.Same with cell phone patents. No need for Apple and others to Duke it out. Etc.Etc.Although this judge has a good record on decisions standing , what is her record for pharmaceutical patients ?
An interesting perspective
An interesting perspective
Sad but true Amrn has always had a Debby downer syndrome. The trial results surprised everybody even Amrn for one example. Kind of a Seabiscuit horse story.Nobody thinks they can win until they do. Same with sales. The demand is there to justify a much higher estimated stock price but most won't believe it till they see it then the opportunity will have passed by.
Sorry to hear about your loss. Us humans sometimes we go along thinking we are immune then our heart reminds us we are not immune
What really makes happiness isn't money it's the miracle of your son. I'm sure he feels the same about you.
Had to laugh!! So true. Its like you have said many times the science is consistent and it hasn't changed."stick to the normal speculating and bickering that frames this MB..."
I agree with JL regarding the science issues the m o Etc. However let's not forget the opiate epidemic caused in large apart by the production companies that are now answering for in court xcetera.. one of my buddies paid the ultimate price for the get-rich-quick opioid drug companies. So I can understand why people would want the FDA to get it right
Hard to imagine Amarin will blind walk into another booby trap again. They will be ready this time.
No corruption? Look into the Monsanto roundup mess.they now have lost three lawsuits to the tune of around 80 million each.13000 more in que. Had the EPA run a proper trial Round up and GMOs would not be in the food supply.Maybe the FDA is trying to get it right but I wouldn't hold your breath on that.
If your going to play with the big boys investing in a company like Amrn stop losses are a bad idea imo.
The market really doesn't understand vascepa they still think it's just a fish oil pill and they treated like that. Once it gets approved that's another story. The science is very sound I've always thought it was. The fact is no other quote-unquote fish oil drug has succeeded like vascepa. The stigma remains in the mind of most. However as the sales Skyrocket and they will the share price will also rise in parallel. It's all about the dough. Amrn has had to prove it all along and grind it out. It would not surprise me that it will continue to happen for a time.
I might add that Amarin son will have ample funds to keep attorneys in court and litigate for however long it takes. Do you really think some cheesy little investment fund group can afford to stay in court with Amarin for the foreseeable future?
Vacepa is already been approved for one indication. If it were such a great idea so that generics really wanted to jump in why haven't they done so already? Maybe because JL is right. It's not such a great idea. Apparently their attorneys don't think so either or they'd be in court right now.
Just a reminder AMRN and vascepa has a long history of doubters. So it's been relatively easy 4 shorts to use scare tactics to get a downward movement especially on the back of a downswing of the broader Market. In my opinion this will all change when vascepa is approved it's sales Skyrocket Etc. As far as patent challenges go this is already been attempted by far more expert people already and they have failed. I've been tempted to trade on many of these fluctuations. The uncertainty of the whole vascepa story has stopped me. I am long and remain long . I predict they'll be plenty of money at the end of the adventure. By the time it's realized what a winner this is it's going to be too late for most. Playing the short game for small investors like me is just chump change compared to the payoff that's coming
Just a wild guess by a total amateur. Amarin for understandable reasons is being extremely careful to do everything by the book. That way if and when they have to litigate once again they will have their ducks in a row. I'm sure they want no reasons for any further delays of the expanded label.
Which one of those has the market potential of AMRN? That's right none of them.
Buyouts? Amarin and the Baker bros are pros. Successful phase 3.etc.Huge market. Do you really think they and the longs are going to consent to some chump change buyout? Based on current pps share estimates. The street really hasn't a clue what Amarin is worth. Cool thing is this rumor is at least educating the street a little. Be interesting if the street finally does figure out what Amarin is really worth.
Are Conservative projections a way to protect the company ? Amrn does not have the resources to protect itself from multiple lawsuits over overzealous projections. Amrn somehow has survived being put through a gauntlet. Imo they may be just being careful. They have successfully gotten this far. Why deliberately create problems for yourself ? Like my momma said until it's in your hand you don't own it! I've waited all these years what's a few more months? Most realize Vacepas potential has been proven. Once the regulatory hurdle is cleared the pot of gold will be here.
Hard for the market to price in all the wild talk and actions.Seems things need to get back on an even keel.Who knows if and when that will happen. So glad RI results preceded this nonsense, and the capital raise turned out to be a very good very timely move. If sales take off Amrn will be just fine.
Thanks for posting this I think the dynamic of the spa debacle along with the biased negative commentators has obscured this pearl of high value. If you want in nows the time!
Good time to pick up more shares
Amrn the dark horse. Right now it's risk off in the market. Until the FDA decides to cough up the expanded label etc. Amrn always has been and will continue to be a high risk investment, one that gets dumped 1st in a down market. I believe in the science.Kind of hard to count on the rule of law anymore. Opioids are causing havoc yet like big tobacco the whole supply chain is being sued in effort to stop obvious abuse. Why is it happening ? MONEY!!! So IMO until Amrn=MONEY its going to be the Rodney Dangerfield of stocks. That means sales,expanded label etc.Then and only then will the share price hold up in a down market.
Yes as much as the past upsets us or me , the future lies in getting the word out about the trial results. That will make it very unlikely anything like that will occur again
Secondary endpoints ? Didn't Amrn specifically ask for the trial NOT to end early? Why? Because they wanted to establish data for other indications.They also applied for a number of other patents for those uses? In effect they already have other indications in the pipeline they own. I'm just a Barney in the approval process , bit it seems to me that was their intention.
I second that!! They days of slug slow tech are over. GM for example having to cut in mass expert employee's due to rapid changes brought about by the modern integration of hi tech to vehicles.By trade I am a40 yr master autotech. With the rapid fire changes I am constantly having to retrain.I almost can't survive without the internet and constant scan tool upgrades. The day of 1950s business models are dead and gone.Amarin is doing businesses the new way and they are going to kick but. If you want to stand in front of the Amarin train go ahead , we will recycle the grease spot that results.
Absolutely!! Its nice to see technical discussion. However the dark cloud over Vacepa has been blown out of the sky. Just seems investors are having a hard time accepting it. Crazy at this point you can still initiate a position in AMRN with so much upside potential. If it were any other drug it would be too late. Incredible the investment rags are still pumping out mindless disproven FAKE trash about Vacepa. Don't these writers ever do their homework? It makes me glad to see a going it alone mindset from AMRN. They are the only ones who really know the drug and have 1st hand experience marketing it. I know sales force size matters but correctness can be way more effective.
The Adcom is on YouTube Watch it and see the rigged no vote that has cost thousands of lives.Amarin I'm sure will slowly prepare and make sure that there is no excuse for a rejection this time
Vacepa Adcom is on YouTube. Watch it and see the rigged no vote that has cost thousands of lives.I'm sure Amarin is very well aware that one miss step could be catastrophic. They take their time and will make sure everything is in perfect order this time.
AMARIN IS HOLDING ALL THE CARDS.Same crap offers as years ago low ball offers. Only this time Amarin is hold ALL THE CARDS. They can name their price and it won't be low ball. IMO no one knows the correct valuation not even AMARIN. they haven't even assessed all the indications yet. 80 could be chump change. Highly doubtful JT will jump for some stupid rip off deal.
Modernisation of sales methods it seems are not being taken into account. Is a vast sales force really needed with Vascepa? These days some newsworthy events are well known almost hourly.Times are changing so fast in this way. Brick and mortar stores are dropping like flies. Why? The internet has changed the playing field.People shop online. With all the mass communication now available for almost free the news about Vacepa will not require some big pharma buyout sales force. In principle think of all the silly stuff that becomes known world wide in an instant.Some celebrity does some stupid stunt and every nation knows about it within minutes.Amazing how slow companies are to recognize this.the success of Amarin sales will depend on how well they understand and utilize the internet.The days of big box pharma are probably numbered just like every other big box sales slug out there
Really JT sees the need to focus on the goal. Which is convincing and publicizing Vacepa to1 MDS 2 To the public. The rest will follow
MSNBC commercial for Vasepa aired mentioned the studies etc.
JT SPEAKS https://finance.yahoo.com/video/amarin-ceo-comments-medicines-mixed-173900775.html
in case you didn't see it
That's true , its the main stream MD's who have to get on board. Unfortunately society tends to suck up what commerce feeds it whether it's true science or not. But kinda hard to believe MD's will pay more attention to the trash talk than 25% benefit. IMO the 25% benefit will catch MD's ears like a fire storm.
My wild guess is next quarter report. Scripts will lite this thing up big.
No strong evidence for biological activity of mineral oil was identified • in connection with FDA approval of Vascepa in July 2012 based on the MARINE phase 3 clinical trial, • in connection with FDA review of the ANCHOR phase 3 clinical trial or • after several years of quarterly review by the Data Monitoring Committee, or DMC, for REDUCEIT cardiovascular outcomes trial after FDA requested the DMC to periodically review unblinded lipid data to monitor for signals that the placebo might not be inert. Each of the three Vascepa clinical trials, MARINE, ANCHOR and REDUCE-IT, was conducted under a special protocol, or SPA, agreement with FDA in which mineral oil was agreed with FDA as an acceptable placebo. A SPA is an evaluation by the FDA of a protocol with the goal of reaching an agreement that the trial protocol design, clinical endpoints, and statistical analyses are acceptable to support regulatory approval of the drug product candidate with respect to effectiveness for the indication studied.
Well said, those of us who have been here for years know that AMRN has a stigma as a highly speculative stock. On weak market days AMRN moves down more than most. Look at the NASDAC chart last few days then compare. The Vacepa science has been proven , just have to wait for the process to compete,,, It will be well worth the wait.